Chemistry: molecular biology and microbiology – Virus or bacteriophage – except for viral vector or...
Reexamination Certificate
2007-06-20
2011-12-06
Lucas, Zachariah (Department: 1648)
Chemistry: molecular biology and microbiology
Virus or bacteriophage, except for viral vector or...
C435S239000
Reexamination Certificate
active
08071352
ABSTRACT:
The present invention relates to a novel bacteriophage, more precisely a novel bacteriophage having killing activity specific toStaphylococcus aureuswhich is the causing agent of infectious diseases in human and animals, a pharmaceutical composition for the prevention and treatment of the disease caused byStaphylococcus aureus, an antibiotic and a disinfectant containing the bacteriophage as an active ingredient.
REFERENCES:
patent: 6056954 (2000-05-01), Fischetti
patent: 6056955 (2000-05-01), Fischetti
patent: 6121036 (2000-09-01), Ghanbari
patent: 6264945 (2001-07-01), Fischetti
patent: 6432444 (2002-08-01), Fischetti et al.
patent: 7572602 (2009-08-01), Donovan
patent: 7582291 (2009-09-01), Yoong
patent: 2003/0152594 (2003-08-01), Pillich
patent: 2003/0216338 (2003-11-01), Merril
patent: 2004/0091470 (2004-05-01), Fischetti et al.
patent: 2004/0146490 (2004-07-01), Kelly
patent: 2005/0260171 (2005-11-01), Ghanbari et al.
patent: 2007/0025978 (2007-02-01), Yoong
patent: 2007/0077235 (2007-04-01), Loomis
patent: 2010/0004321 (2010-01-01), Ross
patent: 2010/0144619 (2010-06-01), Yoon et al.
patent: 2010/0203019 (2010-08-01), Yoon et al.
patent: 2010/0203180 (2010-08-01), Yoon et al.
patent: 2010/0254950 (2010-10-01), Yoon et al.
patent: 2006-55461 (2006-06-01), None
patent: 2006-73562 (2006-08-01), None
patent: 2007-82358 (2007-08-01), None
patent: 1007-81669 (2007-12-01), None
patent: WO 03/067991 (2003-08-01), None
patent: WO 2004/020451 (2004-03-01), None
patent: WO 2004/062677 (2004-07-01), None
patent: WO 2006/063176 (2006-06-01), None
patent: WO 2007/148919 (2007-12-01), None
patent: WO 2008/016240 (2008-02-01), None
patent: WO 2009/035303 (2009-03-01), None
Bokarewa MI, Jin T, Tarkowski A. (2006)Staphylococcus aureus: Staphylokinase. Int J Biochem Cell Biol. 38(4): 504-509.
KACC 97001P, titled “Staphlococcal Bacteriphase JS”, deposited with the Korean Agricultural Culture Collection on Jun. 12, 2006.
International Search Report for PCT/KR2007/002995 (published as WO 2007/148919) dated Sep. 18, 2007, listing Yoon et al. as inventors and Intron Biotechnology, Inc. as Applicant.
International Preliminary Report on Patentability with Written Opinion for PCT/KR2007/002995 (published as WO 2007/148919) dated Dec. 22, 2008, listing Yoon et al. as inventors and Intron Biotechnology, Inc. as Applicant.
Accession No. KACC 97001P, Staphloccal bacteriophage, (2006).
Accession No. KCTC 11151BP, pBAD-TOPO-SAL1, (2007).
Accession No. KCTC 11152BP,Escherichia colipBAD::Lysin, (2007).
Accession No. KCTC 11153BP, SAP1 bacteriophage, (2007).
Accession No. KCTC 11154BP, SAP2 bacteriophage, (2007).
Arciola CR, Baldassarri L, Montanaro L. (2001) Presence of icaA and icaD genes and slime production in a collection of staphylococcal strains from catheter-associated infections. J Clin Microbiol. 39(6): 2151-2156.
Arciola CR, Montanaro L, Baldassarri L, Borsetti E, Cavedagna D, Donati E. (1999) Slime production by Staphylococci isolated from prosthesis-associated infections. New Microbiol. 22(4): 337-341.
Bernhardt TG, Wang IN, Struck DK, Young R. (2002) Breaking free: “protein antibiotics” and phage lysis. Res Microbiol. 153(8): 493-501.
Cisani G, Varaldo PE, Grazi G, Soro O. (1982) High-level potentiation of lysostaphin anti-staphylococcal activity by lysozyme. Antimicrob Agents Chemother. 21(4): 531-535.
Costerton JW, Lewandowski Z, DeBeer D, Caldwell D, Korber D, James G. (1994) Biofilms, the customized microniche. J Bacteriol. 176(8): 2137-2142.
Cramton SE, Gerke C, Schnell NF, Nichols WW, Götz F. (1999) The intercellular adhesion (ica) locus is present inStaphylococcus aureusand is required for biofilm formation. Infect Immun. 67(10): 5427-5433.
Genbank Accession No. AA047477, titled “Soares pregnant uterus NbHPU”, entered Sep. 19, 1996.
Genbank Accession No. AY176327, titled “Staphylococcusphage K, complete genome”, Direct Submission (See O'Flaherty et al., 2004).
GenBank Accession No. AY954969, titled “Bacteriophage G1, complete genome”, Direct Submission (See Kwan et al., 2005).
Graham S, Coote PJ. (2007) Potent, synergistic inhibition ofStaphylococcus aureusupon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin. J Antimicrob Chemother. 59(4): 759-762.
Gründling A, Missiakas DM, Schneewind O. (2006)Staphylococcus aureusmutants with increased lysostaphin resistance. J Bacteriol. 188(17): 6286-6297.
Kusuma C, Jadanova A, Chanturiya T, Kokai-Kun JF. (2007) Lysostaphin-resistant variants ofStaphylococcus aureusdemonstrate reduced fitness in vitro and in vivo. Antimicrob Agents Chemother. 51(2): 475-482.
Kwan T, Liu J, DuBow M, Gros P, Pelletier J. (2005) The complete genomes and proteomes of 27Staphylococcus aureusbacteriophages. Proc Natl Acad Sci USA. 102(14): 5174-5179.
Loessner MJ, Gaeng S, Scherer S. (1999) Evidence for a holin-like protein gene fully embedded out of frame in the endolysin gene ofStaphylococcus aureusbacteriophage 187. J Bacteriol. 181(15): 4452-4460.
Loessner MJ. (2005) Bacteriophage endolysins—current state of research and applications. Curr Opin Microbiol. 8(4): 480-487.
Mah TF, O'Toole GA. (2001) Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 9(1): 34-39.
Matsuzaki S, Rashel M, Uchiyama J, Sakurai S, Ujihara T, Kuroda M, Ikeuchi M, Tani T, Fujieda M, Wakiguchi H, Imai S. (2005) Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chemother. 11(5): 211-219.
Matsuzaki S, Yasuda M, Nishikawa H, Kuroda M, Ujihara T, Shuin T, Shen Y, Jin Z, Fujimoto S, Nasimuzzaman MD, Wakiguchi H, Sugihara S, Sugiura T, Koda S, Muraoka A, Imai S. (2003) Experimental protection of mice against lethalStaphylococcus aureusinfection by novel bacteriophage phi MR11. J Infect.
McKenney D, Pouliot KL, Wang Y, Murthy V, Ulrich M, Döring G, Lee JC, Goldmann DA, Pier GB. (1999) Broadly protective vaccine forStaphylococcus aureusbased on an in vivo-expressed antigen. 284(5419): 1523-1527.
O'Flaherty S, Coffey A, Edwards R, Meaney W, Fitzgerald GF, Ross RP. (2004) Genome of staphylococcal phage K: a new lineage of Myoviridae infecting gram-positive bacteria with a low G+C content. J Bacteriol. 186(9): 2862-2871.
O'Gara JP, Humphreys H. (2001)Staphylococcusepidermidis biofilms: importance and implications. J Med Microbiol. 50(7): 582-587.
Resch A, Fehrenbacher B, Eisele K, Schaller M, Götz F. (2005) Phage release from biofilm and planktonicStaphylococcus aureuscells. FEMS Microbiol Lett. 252(1): 89-96.
Sass P, Bierbaum G. (2007) Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms ofStaphylococcus aureus. Appl Environ Microbiol. 73(1): 347-352.
Schuch R, Nelson D, Fischetti VA. (2002) A bacteriolytic agent that detects and killsBacillus anthracis. Nature. 418(6900): 884-889.
Severance PJ, Kauffman CA, Sheagren JN. (1980) Rapid identification ofStaphylococcus aureusby using lysostaphin sensitivity. J Clin Microbiol. 11(6): 724-727.
Skurnik M, Strauch E. (2006) Phage therapy: facts and fiction. Int J Med Microbiol. 296(1): 5-14.
Vybiral D, Takác M, Loessner M, Witte A, von Ahsen U, Bläsi U. (2003) Complete nucleotide sequence and molecular characterization of two lyticStaphylococcus aureusphages: 44AHJD and P68. FEMS Microbiol Lett. 219(2): 275-283.
Waldvogel FA. (2000) Infections Associated with Indwelling Medical Devices, pp. 55-88, 2000, ASM, Washington, DC.
Walencka E, Sadowska B, Rózalska S, Hryniewicz W, Rózalska B. (2006)Staphylococcus aureusbiofilm as a target for single or repeated doses of oxacillin, vancomycin, linezolid and/or lysostaphin. Folia Microbiol (Praha). 51(5): 381-386.
Wu JA, Kusuma C, Mond JJ, Kokai-Kun JF. (2003) Lysostaphin disruptsStaphylococcus aureusandStaphylococcus epidermidisbiofilms on artificial surfaces. Antimicrob Agents Chemother. 47(11): 3407-3414.
Yoong P, Schuch R, Nelson D, Fischetti VA. (2004) Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic-r
Choi Yunjaie
Kang Sanghyeon
Kyoung Seabong
Son Jeesoo
Yoon Seongjun
Ballard Spahr LLP
Intron Biotechnology, Inc.
Kinsey White Nicole
Lucas Zachariah
LandOfFree
Bacteriophage having killing activity specific to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bacteriophage having killing activity specific to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bacteriophage having killing activity specific to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4269868